Personalis, Inc. (NASDAQ:PSNL) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.
On March 5, 2026, Personalis, Inc. (NASDAQ:PSNL) saw its price target from Morgan Stanley lowered from $11 to $10. The firm’s analyst maintained an Equal Weight rating on the stock after updating its estimates to reflect an increased 2026 net loss guidance and higher projected long-term operating expenses.
In another development, on March 12, 2026, Personalis, Inc. (NASDAQ:PSNL) announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The study highlighted the effectiveness of its NeXT Personal assay in monitoring breast cancer. It tracks up to 1,800 tumor-specific variants to provide precise risk-stratification. Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D, Personalis, Inc. (NASDAQ:PSNL), gave the following statement:
The results of this study suggest that an ultrasensitive ctDNA assay like NeXT Personal could help patients better understand their response to neoadjuvant therapy, with the potential to help inform the need for additional therapy.
Founded in 2011, Personalis, Inc. (NASDAQ:PSNL) is a cancer genomics leader specializing in ultrasensitive liquid biopsy tests for minimal residual disease (MRD). Its headquarters is in California.
While we acknowledge the potential of PSNL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts
Disclosure: None. Follow Insider Monkey on Google News.
